C2932687||NLRC5
C0596290||cell proliferation
C1515844||AKT
C3271788||VEGF-A signaling pathway
C2239176||hepatocellular carcinoma
C2932687||NLRC5
C4277661||NLR family
C1148916||nucleotide-binding
C0684224||reported
C0301872||immune responses
C2239176||hepatocellular carcinoma
C2239176||hepatocellular carcinoma
C0037080||signaling pathways
C2932687||NLRC5
C2239176||hepatocellular carcinoma
C0178874||progression
C1171362||expression
C2932687||NLRC5
C0078058||vascular endothelial growth factor-A
C0078058||vascular endothelial growth factor-A
C0086418||human
C2239176||hepatocellular carcinoma
C0040300||tissue
C1446409||positive
C2932687||NLRC5
C0078058||vascular endothelial growth factor-A
C1171362||expression
C0596290||cell proliferation
C2932687||NLRC5
C1514559||overexpressing
C2717940||HepG2 cells
C0007634||cells
C2932687||NLRC5
C0598496||silencing
C0041904||up-regulation
C2932687||NLRC5
C0251991||AKT inhibitor LY294002
C0078058||vascular endothelial growth factor-A
C1171362||expression
C0164786||AKT
C1158886||phosphorylation
C2717940||HepG2 cells
C2932687||NLRC5
C1514559||overexpressing
C2717940||HepG2 cells
C2932687||NLRC5
C2239176||hepatocellular carcinoma
C0178874||progression
C1515844||AKT
C3271788||VEGF-A signaling pathway